201 related articles for article (PubMed ID: 21206484)
1. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs.
Hicks MJ; De BP; Rosenberg JB; Davidson JT; Moreno AY; Janda KD; Wee S; Koob GF; Hackett NR; Kaminsky SM; Worgall S; Toth M; Mezey JG; Crystal RG
Mol Ther; 2011 Mar; 19(3):612-9. PubMed ID: 21206484
[TBL] [Abstract][Full Text] [Related]
2. Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity.
De BP; Pagovich OE; Hicks MJ; Rosenberg JB; Moreno AY; Janda KD; Koob GF; Worgall S; Kaminsky SM; Sondhi D; Crystal RG
Hum Gene Ther; 2013 Jan; 24(1):58-66. PubMed ID: 23140508
[TBL] [Abstract][Full Text] [Related]
3. Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus.
Koob G; Hicks MJ; Wee S; Rosenberg JB; De BP; Kaminsky SM; Moreno A; Janda KD; Crystal RG
CNS Neurol Disord Drug Targets; 2011 Dec; 10(8):899-904. PubMed ID: 22229312
[TBL] [Abstract][Full Text] [Related]
4. Combined cocaine hydrolase gene transfer and anti-cocaine vaccine synergistically block cocaine-induced locomotion.
Carroll ME; Zlebnik NE; Anker JJ; Kosten TR; Orson FM; Shen X; Kinsey B; Parks RJ; Gao Y; Brimijoin S
PLoS One; 2012; 7(8):e43536. PubMed ID: 22912888
[TBL] [Abstract][Full Text] [Related]
5. Cocaine vaccine dAd5GNE protects against moderate daily and high-dose "binge" cocaine use.
Havlicek DF; Rosenberg JB; De BP; Hicks MJ; Sondhi D; Kaminsky SM; Crystal RG
PLoS One; 2020; 15(11):e0239780. PubMed ID: 33253224
[TBL] [Abstract][Full Text] [Related]
6. Investigations into the efficacy of multi-component cocaine vaccines.
Kimishima A; Olson ME; Janda KD
Bioorg Med Chem Lett; 2018 Sep; 28(16):2779-2783. PubMed ID: 29317163
[TBL] [Abstract][Full Text] [Related]
7. AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior.
Rosenberg JB; Hicks MJ; De BP; Pagovich O; Frenk E; Janda KD; Wee S; Koob GF; Hackett NR; Kaminsky SM; Worgall S; Tignor N; Mezey JG; Crystal RG
Hum Gene Ther; 2012 May; 23(5):451-9. PubMed ID: 22486244
[TBL] [Abstract][Full Text] [Related]
8. Hapten optimization for cocaine vaccine with improved cocaine recognition.
Ramakrishnan M; Kinsey BM; Singh RA; Kosten TR; Orson FM
Chem Biol Drug Des; 2014 Sep; 84(3):354-63. PubMed ID: 24803171
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter.
Maoz A; Hicks MJ; Vallabhjosula S; Synan M; Kothari PJ; Dyke JP; Ballon DJ; Kaminsky SM; De BP; Rosenberg JB; Martinez D; Koob GF; Janda KD; Crystal RG
Neuropsychopharmacology; 2013 Oct; 38(11):2170-8. PubMed ID: 23660705
[TBL] [Abstract][Full Text] [Related]
10. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.
Matthews QL; Yang P; Wu Q; Belousova N; Rivera AA; Stoff-Khalili MA; Waehler R; Hsu HC; Li Z; Li J; Mountz JD; Wu H; Curiel DT
Virol J; 2008 Aug; 5():98. PubMed ID: 18718011
[TBL] [Abstract][Full Text] [Related]
11. Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine.
Hicks MJ; Kaminsky SM; De BP; Rosenberg JB; Evans SM; Foltin RW; Andrenyak DM; Moody DE; Koob GF; Janda KD; Ricart Arbona RJ; Lepherd ML; Crystal RG
Hum Gene Ther Clin Dev; 2014 Mar; 25(1):40-9. PubMed ID: 24649839
[TBL] [Abstract][Full Text] [Related]
12. Cocaine Vaccine Development: Evaluation of Carrier and Adjuvant Combinations That Activate Multiple Toll-Like Receptors.
Kimishima A; Wenthur CJ; Eubanks LM; Sato S; Janda KD
Mol Pharm; 2016 Nov; 13(11):3884-3890. PubMed ID: 27717287
[TBL] [Abstract][Full Text] [Related]
13. Exploring the feasibility of an anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2beta anti-idiotypic antibodies.
Schabacker DS; Kirschbaum KS; Segre M
Immunology; 2000 May; 100(1):48-56. PubMed ID: 10809958
[TBL] [Abstract][Full Text] [Related]
14. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide.
Lasarte JJ; Corrales FJ; Casares N; López-Díaz de Cerio A; Qian C; Xie X; Borrás-Cuesta F; Prieto J
J Immunol; 1999 May; 162(9):5270-7. PubMed ID: 10228002
[TBL] [Abstract][Full Text] [Related]
15. Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides.
Espenlaub S; Wortmann A; Engler T; Corjon S; Kochanek S; Kreppel F
J Gene Med; 2008 Dec; 10(12):1303-14. PubMed ID: 18837065
[TBL] [Abstract][Full Text] [Related]
16. Anti-cocaine vaccine development.
Kinsey BM; Kosten TR; Orson FM
Expert Rev Vaccines; 2010 Sep; 9(9):1109-14. PubMed ID: 20822352
[TBL] [Abstract][Full Text] [Related]
17. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.
Crosby CM; Nehete P; Sastry KJ; Barry MA
J Virol; 2015 Jan; 89(1):669-75. PubMed ID: 25355873
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a therapeutic cocaine vaccine in rodent models.
Fox BS; Kantak KM; Edwards MA; Black KM; Bollinger BK; Botka AJ; French TL; Thompson TL; Schad VC; Greenstein JL; Gefter ML; Exley MA; Swain PA; Briner TJ
Nat Med; 1996 Oct; 2(10):1129-32. PubMed ID: 8837612
[TBL] [Abstract][Full Text] [Related]
19. Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure.
Wirtz S; Galle PR; Neurath MF
Gut; 1999 Jun; 44(6):800-7. PubMed ID: 10323880
[TBL] [Abstract][Full Text] [Related]
20. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.
Rosenberg JB; De BP; Hicks MJ; Janda KD; Kaminsky SM; Worgall S; Crystal RG
Hum Gene Ther; 2013 Jun; 24(6):595-603. PubMed ID: 23611296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
